Authors: Tu, SM Millikan, RE Mengistu, B Delpassand, ES Amato, RJ Pagliaro, LC Daliani, D Papandreou, CN Smith, TL Kim, J Podoloff, DA Logothetis, CJ

Citation: Sm. Tu et al., Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial, LANCET, 357(9253), 2001, pp. 336-341

Authors: Usmani, BA Shen, RQ Janeczko, M Papandreou, CN Lee, WH Nelson, WG Nelson, JB Nanus, DM

Citation: Ba. Usmani et al., Methylation of the neutral endopeptidase gene promoter in human prostate cancers, CLIN CANC R, 6(5), 2000, pp. 1664-1670

Authors: Shen, RQ Sumitomo, M Dai, J Hardy, DO Navarro, D Usmani, B Papandreou, CN Hersh, LB Shipp, MA Freedman, LP Nanus, DM

Citation: Rq. Shen et al., Identification and characterization of two androgen response regions in the human neutral endopeptidase gene, MOL C ENDOC, 170(1-2), 2000, pp. 131-142

Authors: Sumitomo, M Shen, RQ Walburg, M Dai, J Geng, YP Navarro, D Boileau, G Papandreou, CN Giancotti, FG Knudsen, B Nanus, DM

Citation: M. Sumitomo et al., Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling, J CLIN INV, 106(11), 2000, pp. 1399-1407

Authors: Usmani, BA Janeczko, M Shen, R Mazumdar, M Papandreou, CN Nanus, DM

Citation: Ba. Usmani et al., Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer, BR J CANC, 82(3), 2000, pp. 550-552

Authors: Daliani, D Papandreou, CN

Citation: D. Daliani et Cn. Papandreou, Markers of androgen-independent progression of prostatic carcinoma, SEMIN ONCOL, 26(4), 1999, pp. 399-406